Brief: Sino Biopharmaceutical Says Tqg3902 Angiotensin II Injection Approved For Clinical Trial
01/11/2023 15:30
Nov 1 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK :
* TQG3902 "ANGIOTENSIN II" INJECTION APPROVED FOR CLINICAL
TRIAL
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up